Teleflex (NYSE:TFX) Stock Rating Raised to Strong-Buy at Zacks Research

Teleflex (NYSE:TFX) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday, Zacks reports.

Other analysts have also issued reports about the stock. Needham & Company LLC upped their price objective on shares of Teleflex from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Mizuho raised their target price on shares of Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Monday. UBS Group upped their price target on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $152.90.

Teleflex Stock Performance

Shares of NYSE:TFX opened at $122.44 on Thursday. The firm has a market cap of $5.19 billion, a PE ratio of -5.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.82. The firm’s 50 day simple moving average is $134.00 and its 200-day simple moving average is $128.54. Teleflex has a one year low of $100.18 and a one year high of $145.00. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. The firm had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.Teleflex’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities analysts predict that Teleflex will post 7.26 EPS for the current year.

Hedge Funds Weigh In On Teleflex

Large investors have recently added to or reduced their stakes in the company. Kelleher Financial Advisors purchased a new stake in shares of Teleflex during the second quarter valued at about $25,000. Allworth Financial LP purchased a new position in shares of Teleflex in the 2nd quarter worth approximately $44,000. Hantz Financial Services Inc. raised its stake in shares of Teleflex by 40.5% during the 4th quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after acquiring an additional 113 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Teleflex by 573.4% during the 2nd quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company’s stock worth $55,000 after acquiring an additional 367 shares in the last quarter. Finally, Trust Co. of Vermont purchased a new stake in Teleflex during the second quarter valued at approximately $57,000. 95.62% of the stock is currently owned by institutional investors.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.